未成熟卵母细胞体外成熟在生育力保护中的应用进展

doi:10.3969/j.issn.1006-7795.2022.03.001

摘要/Abstract

摘要： 卵巢组织冻存与移植技术已常规用于早发性卵巢功能不全风险高的女童和年轻女性患者进行生育力保护,冻存的卵巢皮质复苏后自体移植可恢复生育力和内分泌功能,但卵巢转移风险高的患者卵巢组织移植再引入恶性细胞的风险高。冷冻的卵巢皮质中主要含有原始卵泡,但也可以在卵巢组织处理过程中从小窦卵泡中获取未成熟卵母细胞,已有活产通过卵巢组织卵母细胞体外成熟(in vitro matured ovarian tissue oocytes, OTO-IVM)技术诞生,双相体外成熟(in vitro maturation, IVM)即获能(capacitation, CAPA)-IVM系统显著优化了卵母细胞IVM系统。在移植风险高的情况下,通过从生长卵泡中获取卵母细胞进行IVM,可以安全地恢复生育力,这将最大限度地发挥所有生育力保护患者的潜力。但OTO-IVM的证据仍有限,需证实其重复性,随访OTO-IVM儿童。本文主要综述人未成熟卵母细胞体外成熟在生育力保护中的应用进展。

关键词: 未成熟卵母细胞, 体外成熟, 生育力保护, 卵巢组织冻存

Abstract: Ovarian tissue cryopreservation and transplantation has been routinely used for fertility preservation in girls and young female patients with high risk of premature ovarian insufficiency. Autotransplantation of cryopreserved ovarian cortex after thawed can restore fertility and endocrine function. However, patients with high risk of ovarian metastasis have a higher risk of reintroducing malignant cells. The frozen ovarian cortex mainly contains primordial follicles, but immature oocytes can also be obtained from small antral follicles during ovarian tissue preparation. Some live births have been born through in vitro matured of ovarian tissue oocytes (OTO-IVM). Biphasic in vitro maturation (IVM) capacitation (CAPA)-IVM system significantly optimizes the IVM system. In the case of high risk of transplantation, IVM of oocytes from growing follicles can safely restore fertility, which will maximize the potential of all fertility preservation patients. However, the evidence of OTO-IVM is still limited and its repeatability needs to be confirmed. Children with OTO-IVM are followed up. This article mainly reviews the application progress of in vitro maturation of human immature oocytes for fertility preservation.

Key words: immature oocytes, in vitro maturation, fertility preservation, ovarian tissue cryopreservation

中图分类号:

R711.75

程姣姣, 阮祥燕, 杜娟, 谷牧青. 未成熟卵母细胞体外成熟在生育力保护中的应用进展[J]. 首都医科大学学报, 2022, 43(3): 329-335.

Cheng Jiaojiao, Ruan Xiangyan, Du Juan, Gu Muqing. Application progress of in vitro maturation of immature oocytes for fertility preservation[J]. Journal of Capital Medical University, 2022, 43(3): 329-335.

参考文献

[1] Burke M J, Devidas M, Chen Z G, et al. Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232[J]. Leukemia, 2022, 36(3): 648-655.
[2] 国际妇科内分泌学会中国妇科内分泌学分会及共识专家. 卵巢组织冻存与移植中国专家共识[J]. 中国临床医生杂志, 2018, 46(4): 496-500.
[3] Donnez J, Dolmans M M. Fertility preservation in women[J]. N Engl J Med, 2017, 377(17): 1657-1665.
[4] Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion[J]. Fertil Steril, 2019, 112(6): 1022-1033.
[5] Pacheco F, Oktay K. Current success and efficiency of autologous ovarian transplantation: a meta-analysis[J]. Reprod Sci, 2017, 24(8): 1111-1120.
[6] Dolmans M M, Donnez J, Cacciottola L. Fertility preservation: the challenge of freezing and transplanting ovarian tissue[J]. Trends Mol Med, 2021, 27(8): 777-791.
[7] Donnez J, Dolmans M M. Fertility preservation in women[J]. N Engl J Med, 2018, 378(4): 400-401.
[8] Michalczyk K, Cymbaluk-Płoska A. Fertility preservation and long-term monitoring of gonadotoxicity in girls, adolescents and young adults undergoing cancer treatment[J]. Cancers (Basel), 2021, 13(2): 202.
[9] Silber S J, DeRosa M, Goldsmith S, et al. Cryopreservation and transplantation of ovarian tissue: results from one center in the USA[J]. J Assist Reprod Genet, 2018, 35(12): 2205-2213.
[10] Shapira M, Raanani H, Barshack I, et al. First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination[J]. Fertil Steril, 2018, 109(1): 48-53.
[11] Gellert S E, Pors S E, Kristensen S G, et al. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort[J]. J Assist Reprod Genet, 2018, 35(4): 561-570.
[12] Trounson A, Wood C, Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients[J]. Fertil Steril, 1994, 62(2): 353-362.
[13] Sauerbrun-Cutler M T, Vega M, Keltz M, et al. In vitro maturation and its role in clinical assisted reproductive technology[J]. Obstet Gynecol Surv, 2015, 70(1): 45-57.
[14] Braam S C, Ho V N A, Pham T D, et al. In-vitro maturation versus IVF: a cost-effectiveness analysis[J]. Reprod Biomed Online, 2021, 42(1): 143-149.
[15] Siristatidis C S, Maheshwari A, Vaidakis D, et al. In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction[J]. Cochrane Database Syst Rev, 2018, 11(11): CD006606.
[16] Practice Committees of the American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. In vitro maturation: a committee opinion[J]. Fertil Steril, 2021, 115(2): 298-304.
[17] Kirillova A, Kovalskaya E, Brovkina O, et al. Cryopreservation of euploid blastocysts obtained after fertilization of in vitro matured ovarian tissue oocytes: a case report[J]. J Assist Reprod Genet, 2020, 37(4): 905-911.
[18] Kornilov N V, Pavlova M N, Yakovlev P P. The live birth in a woman with resistant ovary syndrome after in vitro oocyte maturation and preimplantation genetic testing for aneuploidy[J]. J Assist Reprod Genet, 2021, 38(6): 1303-1309.
[19] Flageole C, Toufaily C, Bernard D J, et al. Successful in vitro maturation of oocytes in a woman with gonadotropin-resistant ovary syndrome associated with a novel combination of FSH receptor gene variants: a case report[J]. J Assist Reprod Genet, 2019, 36(3): 425-432.
[20] Galvão A, Segers I, Smitz J, et al. In vitro maturation (IVM) of oocytes in patients with resistant ovary syndrome and in patients with repeated deficient oocyte maturation[J]. J Assist Reprod Genet, 2018, 35(12): 2161-2171.
[21] Li Y, Pan P, Yuan P, et al. Successful live birth in a woman with resistant ovary syndrome following in vitro maturation of oocytes[J]. J Ovarian Res, 2016, 9(1): 54.
[22] Park C W, Lee S H, Yang K M, et al. Cryopreservation of in vitro matured oocytes after ex vivo oocyte retrieval from gynecologic cancer patients undergoing radical surgery[J]. Clin Exp Reprod Med, 2016, 43(2): 119-125.
[23] Fasano G, Dechène J, Antonacci R, et al. Outcomes of immature oocytes collected from ovarian tissue for cryopreservation in adult and prepubertal patients[J]. Reprod Biomed Online, 2017, 34(6): 575-582.
[24] Cohen Y, Tannus S, Volodarsky-Perel A, et al. Added benefit of immature oocyte maturation for fertility preservation in women with malignancy[J]. Reprod Sci, 2020, 27(12): 2257-2264.
[25] Revel A, Koler M, Simon A, et al. Oocyte collection during cryopreservation of the ovarian cortex[J]. Fertil Steril, 2003, 79(5): 1237-1239.
[26] Nikiforov D, Junping C, Cadenas J, et al. Improving the maturation rate of human oocytes collected ex vivo during the cryopreservation of ovarian tissue[J]. J Assist Reprod Genet, 2020, 37(4): 891-904.
[27] Karavani G, Wasserzug-Pash P, Mordechai-Daniel T, et al. Age-dependent in vitro maturation efficacy of human oocytes-is there an optimal age?[J]. Front Cell Dev Biol, 2021, 9: 667682.
[28] Kedem A, Yerushalmi G M, Brengauz M, et al. Outcome of immature oocytes collection of 119 cancer patients during ovarian tissue harvesting for fertility preservation[J]. J Assist Reprod Genet, 2018, 35(5): 851-856.
[29] De Roo C, Lierman S, Tilleman K, et al. Ovarian tissue cryopreservation in female-to-male transgender people: insights into ovarian histology and physiology after prolonged androgen treatment[J]. Reprod Biomed Online, 2017, 34(6): 557-566.
[30] Walls M L, Douglas K, Ryan J P, et al. In-vitro maturation and cryopreservation of oocytes at the time of oophorectomy[J]. Gynecol Oncol Rep, 2015, 13: 79-81.
[31] Hourvitz A, Yerushalmi G M, Maman E, et al. Combination of ovarian tissue harvesting and immature oocyte collection for fertility preservation increases preservation yield[J]. Reprod Biomed Online, 2015, 31(4): 497-505.
[32] Yin H Q, Jiang H, Kristensen S G, et al. Vitrification of in vitro matured oocytes collected from surplus ovarian medulla tissue resulting from fertility preservation of ovarian cortex tissue[J]. J Assist Reprod Genet, 2016, 33(6): 741-746.
[33] Segers I, Bardhi E, Mateizel I, et al. Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes[J]. Hum Reprod, 2020, 35(9): 2026-2036.
[34] Uzelac P S, Delaney A A, Christensen G L, et al. Live birth following in vitro maturation of oocytes retrieved from extracorporeal ovarian tissue aspiration and embryo cryopreservation for 5 years[J]. Fertil Steril, 2015, 104(5): 1258-1260.
[35] Doyle J O, Richter K S, Lim J, et al. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval[J]. Fertil Steril, 2016, 105(2): 459-466.
[36] Anderson R A, McLaughlin M, Wallace W H B, et al. The immature human ovary shows loss of abnormal follicles and increasing follicle developmental competence through childhood and adolescence[J]. Hum Reprod, 2014, 29(1): 97-106.
[37] Fouks Y, Hamilton E, Cohen Y, et al. In-vitro maturation of oocytes recovered during cryopreservation of pre-pubertal girls undergoing fertility preservation[J]. Reprod Biomed Online, 2020, 41(5): 869-873.
[38] Kirillova A, Smitz J E J, Sukhikh G T, et al. The role of mitochondria in oocyte maturation[J]. Cells, 2021, 10(9): 2484.
[39] Sanchez F, Le A H, Ho V N A, et al. Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles[J]. J Assist Reprod Genet, 2019, 36(10): 2135-2144.
[40] Sánchez F, Lolicato F, Romero S, et al. An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield[J]. Hum Reprod, 2017, 32(10): 2056-2068.
[41] Degerman E, Belfrage P, Manganiello V C. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3)[J]. J Biol Chem, 1997, 272(11): 6823-6826.
[42] Conti M, Andersen C B, Richard F, et al. Role of cyclic nucleotide signaling in oocyte maturation[J]. Mol Cell Endocrinol, 2002, 187(1/2): 153-159.
[43] DiLuigi A, Weitzman V N, Pace M C, et al. Meiotic arrest in human oocytes is maintained by a Gs signaling pathway[J]. Biol Reprod, 2008, 78(4): 667-672.
[44] Kirillova A, Bunyaeva E, Van Ranst H, et al. Improved maturation competence of ovarian tissue oocytes using a biphasic in vitro maturation system for patients with gynecological malignancy: a study on sibling oocytes[J]. J Assist Reprod Genet, 2021, 38(6): 1331-1340.
[45] Vuong L N, Ho V N A, Ho T M, et al.In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial[J]. Hum Reprod, 2020, 35(11): 2537-2547.
[46] De Vos M, Grynberg M, Ho T M, et al. Perspectives on the development and future of oocyte IVM in clinical practice[J]. J Assist Reprod Genet, 2021, 38(6): 1265-1280.
[47] Cadenas J, Nikiforov D, Pors S E, et al. A threshold concentration of FSH is needed during IVM of ex vivo collected human oocytes[J]. J Assist Reprod Genet, 2021, 38(6): 1341-1348.
[48] Akin N, Le A H, Ha U D T, et al. Positive effects of amphiregulin on human oocyte maturation and its molecular drivers in patients with polycystic ovary syndrome[J]. Hum Reprod, 2021, 37(1): 30-43.
[49] Pla I, Sanchez A, Pors S E, et al. Proteome of fluid from human ovarian small antral follicles reveals insights in folliculogenesis and oocyte maturation[J]. Hum Reprod, 2021, 36(3): 756-770.
[50] Goud P T, Goud A P, Qian C, et al.In-vitro maturation of human germinal vesicle stage oocytes: role of cumulus cells and epidermal growth factor in the culture medium[J]. Hum Reprod, 1998, 13(6): 1638-1644.
[51] Zamah A M, Hsieh M, Chen J, et al. Human oocyte maturation is dependent on LH-stimulated accumulation of the epidermal growth factor-like growth factor, amphiregulin[J]. Hum Reprod, 2010, 25(10): 2569-2578.
[52] Xie Q G, Xing Y X, Zhou J H, et al. The effect of lysophosphatidic acid-supplemented culture medium on human immature oocytes matured in vitro[J]. Reprod Biol Endocrinol, 2021, 19(1): 83.
[53] Lee S H. Human adipose-derived stem cells' paracrine factors in conditioned medium can enhance porcine oocyte maturation and subsequent embryo development[J]. Int J Mol Sci, 2021, 22(2): 579.
[54] Rodríguez-Varela C, Labarta E. Clinical application of antioxidants to improve human oocyte mitochondrial function: a review[J]. Antioxidants (Basel), 2020, 9(12): 1197.
[55] Price N L, Gomes A P, Ling AJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function[J]. Cell Metab, 2012, 15(5): 675-690.
[56] Liu Y J, Ji D M, Liu Z B, et al. Melatonin maintains mitochondrial membrane potential and decreases excessive intracellular Ca²⁺ levels in immature human oocytes[J]. Life Sci, 2019, 235: 116810.
[57] Liu M J, Sun A G, Zhao S G, et al. Resveratrol improves in vitro maturation of oocytes in aged mice and humans[J]. Fertil Steril, 2018, 109(5): 900-907.
[58] Al-Zubaidi U, Adhikari D, Cinar O, et al. Mitochondria-targeted therapeutics, MitoQ and BGP-15, reverse aging-associated meiotic spindle defects in mouse and human oocytes[J]. Hum Reprod, 2021, 36(3): 771-784.
[59] Bebbere D, Nieddu S M, Ariu F, et al. 3D liquid marble microbioreactors support in vitro maturation of prepubertal ovine oocytes and affect expression of oocyte-specific factors[J]. Biology (Basel), 2021, 10(11): 1101.